scholarly journals Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode

2000 ◽  
Vol 3 (2) ◽  
pp. 129-134 ◽  
Author(s):  
Saxby Pridmore ◽  
Raimondo Bruno ◽  
Yvonne Turnier-Shea ◽  
Phil Reid ◽  
Mazena Rybak
2004 ◽  
Vol 19 (2) ◽  
pp. 118-119 ◽  
Author(s):  
A. Conca ◽  
W. Hrubos ◽  
J. Di Pauli ◽  
P. König ◽  
A. Hausmann

AbstractResearch on repetitive transcranial magnetic stimulation (rTMS) indicates that the treatment of non-psychotic depression is comparable to electroconvulsive therapy (ECT) in terms of short-term outcome. We report on a woman who exerted a recurrent moderate major depressive episode, 6 months after discontinuation of maintenance ECT. She responded to acute rTMS treatment which was followed by the rTMS maintenance-protocol. Within 2 months of continuation rTMS she relapsed suffering from a severe non psychotic depressive episode and had to be switched to a successful ECT. In this patient rTMS had a good clinical impact as an acute treatment strategy, but failed to prevent relapse as the continuation ECT previously did in the same patient.


2019 ◽  
Vol 27 (3) ◽  
pp. 297-301 ◽  
Author(s):  
Tamara May ◽  
Saxby Pridmore

Objectives: This study aimed to explore the effects of a four-week course of transcranial magnetic stimulation (TMS) on the following symptoms of major depressive episode (MDE): mood, work activities, health concerns, guilt, anxiety and retardation. Method: Patients underwent 20 daily sessions of 10 Hz TMS (two sets of 10 daily treatments separated by two days of rest). The six-item Hamilton Depression Rating Scale (HAMD-6) was administered before and after treatment. Remission was operationalised as a HAMD-6 score of <4. Descriptive statistics and t-tests were used to compare pre/post scores on HAMD-6 subscales, and logistic regression was used to understand symptoms that predicted remission/non-remission. Results: There were 104 participants (79 female; 76%), with a mean age of 44.6 years ( SD=15.7 years). There was a significant improvement in the whole sample and in remitters ( n=70) on all subscales. However, those who failed to remit did not achieve significant reductions in ‘health concerns’ and ‘retardation’. There were no difference in age and sex between remitters and non-remitters. Also, there were no significant differences between the remitters and non-remitters on the pretreatment depression symptom profiles. No predictors of response were identified, as expected. Conclusions: TMS has the ability to reduce all listed MDE symptoms. No pretreatment MDE symptom profile was identified which might carry prognostic value.


Sign in / Sign up

Export Citation Format

Share Document